Acolbifene/prasterone: Difference between revisions
CSV import |
CSV import |
||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 03:25, 17 March 2025
Acolbifene/prasterone is a combination of two drugs, acolbifene and prasterone, used in the treatment of vulvovaginal atrophy and sexual dysfunction in postmenopausal women.
Etymology[edit]
The term "acolbifene" is derived from the chemical name of the drug, which is 4-acetoxy-N,N-bis(2-chloroethyl)benzamide. The term "prasterone" is derived from the chemical name of the drug, which is 3β-hydroxyandrost-5-en-17-one.
Pharmacology[edit]
Acolbifene is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects in the breast and uterus. It is used to treat and prevent breast cancer and osteoporosis in postmenopausal women. Prasterone, also known as dehydroepiandrosterone (DHEA), is a steroid hormone that is converted into androgens and estrogens in the body. It is used to treat a variety of conditions, including adrenal insufficiency, depression, osteoporosis, and sexual dysfunction.
Clinical Use[edit]
The combination of acolbifene and prasterone is used to treat vulvovaginal atrophy and sexual dysfunction in postmenopausal women. Vulvovaginal atrophy is a condition characterized by the thinning, drying, and inflammation of the vaginal walls due to a decrease in estrogen. Sexual dysfunction in postmenopausal women can include a decrease in sexual desire, arousal, and satisfaction, as well as pain during sexual intercourse.
Side Effects[edit]
Possible side effects of acolbifene/prasterone include hot flashes, vaginal bleeding, breast pain, and nausea. More serious side effects can include blood clots, stroke, and endometrial cancer.
